SCHEMBL20919927

SCHEMBL20919927

O=C(ON1C(=O)C2C(C1=O)[C@H]1C=C[C@@H]2C1)ON1C(=O)C2C(C1=O)[C@H]1C=C[C@@H]2C1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
TDP1 Q9NUW8 1/20 0.57
SMN1; SMN2 Q16637 6/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
RAB9A P51151 2/20 0.50
MAPK1 P28482 1/20 0.49
PKM P14618 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 4/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 1/20 0.44
RECQL P46063 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13700490 1.00 ALDH1A1 (0.57) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL21987044 1.00 ALDH1A1 (0.57) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL27345844 0.90 SMN1; SMN2 (0.56) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL21987045 0.87 ALDH1A1 (0.55) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL20919929 0.87 ALDH1A1 (0.55) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL21987047 0.87 ALDH1A1 (0.55) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL2584632 0.87 ALDH1A1 (0.55) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL9611853 0.85 ALDH1A1 (0.46) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL4445730 0.85 ALDH1A1 (0.46) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL9250588 0.85 ALDH1A1 (0.46) ALDH1A1TDP1SMN1; SMN2L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174615-A1 SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-30 US disclosed
EP-4320101-A2 SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS Revolution Medicines, Inc. (US) 2024-02-14 EP disclosed
US-20230074115-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2023-03-09 US disclosed
WO-2022216900-A2 SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS Revolution Medicines, Inc. (US) 2022-10-13 WO disclosed
US-20200317652-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2020-10-08 US disclosed
EP-3697797-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. (US) 2020-08-26 EP disclosed
WO-2019079613-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317652-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, SPOUT1, AARS1 ALDH1A1 3668/4885TDP1 2893/4885SMN1; SMN2 4634/4885
US-20230074115-A1 SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, SPOUT1, AARS1 ALDH1A1 3668/4885TDP1 2893/4885SMN1; SMN2 4634/4885
US-20240174615-A1 SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS MLST8, MTOR, RICTOR ALDH1A1 4721/4885TDP1 2289/4885SMN1; SMN2 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.